<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859323</url>
  </required_header>
  <id_info>
    <org_study_id>SHP681-101</org_study_id>
    <nct_id>NCT03859323</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (GLP-2 Analog-Fc Fusion) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and tolerability of single and multiple&#xD;
      ascending subcutaneous (SC) doses of SHP681 in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a single ascending dose (SAD) portion and a multiple ascending dose&#xD;
      (MAD) portion.&#xD;
&#xD;
      The study duration for the SAD portion of the study consists of a screening period of up to&#xD;
      28 days and 1 treatment period of 29 days. SAD portion of the study contains 5 cohorts and&#xD;
      dose escalation will proceed sequentially to assess the following single SC doses of SHP681&#xD;
      or SHP681 matched placebo: 0.2 milligram per kilogram (mg/kg), 0.5 mg/kg, 1 mg/kg, 2 mg/kg,&#xD;
      and 4 mg/kg.&#xD;
&#xD;
      The study duration of the MAD portion comprises of a screening period up to 28 days and a&#xD;
      treatment period of 57 days for each cohort. MAD portion of the study contains 6 cohorts and&#xD;
      dose escalation will proceed sequentially to assess the following SC doses of SHP681 or&#xD;
      SHP681 matched placebo: 0.2 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, and 4 mg/kg once weekly for 5&#xD;
      weeks till 5 cohorts and the 6th cohort will receive 4 mg/kg SHP681 or matched placebo every&#xD;
      2 weeks over a 6-week period (3 doses).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Actual">January 6, 2020</completion_date>
  <primary_completion_date type="Actual">January 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Based on Severity to SHP681 in Single Ascending Dose (SAD)</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 29 for SAD)</time_frame>
    <description>Adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with study or use of investigational drug product (IP), whether or not the AE was considered related to IP. TEAEs: AEs occurring or worsening at or after first dose of IP or ongoing at time of enrollment. SAE :untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. Severity: Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Based on Severity to SHP681 in Multiple Ascending Dose (MAD)</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 57 for MAD)</time_frame>
    <description>AE was any unfavorable and unintended sign, symptom, or disease temporally associated with study or use of investigational drug product (IP), whether or not the AE was considered related to IP. TEAEs: AEs occurring or worsening at or after first dose of IP or ongoing at time of enrollment. SAE :untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. Severity: Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-drug Antibody (ADA) to SHP681 in Single Ascending Dose (SAD) at Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Antibody testing was conducted using an electro chemiluminescent signal method. Number of participants with ADA to SHP681 in SAD at Day 29 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-drug Antibody (ADA) to SHP681 in Multiple Ascending Dose (MAD) at Day 36</measure>
    <time_frame>Day 36</time_frame>
    <description>Antibody testing was conducted using an electro chemiluminescent signal method. Number of participants with ADA to SHP681 in MAD at Day 36 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-drug Antibody (ADA) to SHP681 in Multiple Ascending Dose (MAD) at Day 57</measure>
    <time_frame>Day 57</time_frame>
    <description>Antibody testing was conducted using an electro chemiluminescent signal method. Number of participants with ADA to SHP681 in MAD at Day 57 were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
    <description>Cmax of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the Last Measurable Concentration (Tlast) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
    <description>tlast of SHP681 during SAD was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
    <description>tmax of SHP681 during SAD was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-last) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
    <description>AUC0-last of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Extrapolated to Infinity (AUC0-inf) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
    <description>AUC0-inf of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
    <description>t1/2 of SHP681 during SAD was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration From Time Zero to 24 Hours Post Dose (Cavg,0-24) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24 hours post-dose</time_frame>
    <description>Cavg,0-24 of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Order Rate Constant Associated With the Terminal (Log-linear) Portion of the Curve (Lambda z) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
    <description>Lambda z of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance for Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as Dose Divided by AUC0-inf (CL/F) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
    <description>CL/F of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution Following Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as CL/F Divided by Lambda z (Vz/F) of SHP681 During Single Ascending Dose (SAD)</measure>
    <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
    <description>Vz/F of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration From Time Zero to 24 Hours Post First Dose (Cavg,0-24) of SHP681 Post First Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24 hours post-dose on Day 1</time_frame>
    <description>Cavg,0-24 of SHP681 post first dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Concentration at the End of Each Dosing Interval (Immediately Before Next Dose) (Ctrough) of SHP681 for the First 5 Cohorts and Immediately Before 2nd and 3rd Dose of the 6th MAD Cohort During Multiple Ascending Dose (MAD)</measure>
    <time_frame>Pre-dose on Days 8, 15, 22 and 29</time_frame>
    <description>Ctrough of SHP681 for the First 5 cohorts and immediately before 2nd and 3rd dose of the 6th MAD cohort during MAD was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration During the Dosing Interval Occurring at Tmax (Cmax) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>Cmax of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the Last Measurable Concentration (Tlast) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>Tlast of SHP681 post fifth dose during MAD was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>tmax of SHP681 post fifth dose during MAD was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for the Defined Interval Between Doses (Only Calculated if Interpretable) (AUC0-tau) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>AUC0-tau of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-last) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>AUC0-last of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Extrapolated to Infinity (AUC0-inf) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>AUC0-inf of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration From Time Zero to 24 Hours Post Dose (Cavg,0-24) of SHP681 During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>Cavg,0-24 of SHP681 during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>t1/2 of SHP681 post fifth dose during MAD was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Order Rate Constant Associated With the Terminal (Log-linear) Portion of the Curve (Lambda z) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>Lambda z of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance Following Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as Dose Divided by AUCtau (CL/F) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>CL/F of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution Following Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as CL/F Divided by Lambda z (Vz/F) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
    <description>Vz/F of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD): 0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single subcutaneous (SC) injection of 0.2 mg/kg SHP681 in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD): 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single SC injection of 0.5 mg/kg SHP681 in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD): 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single SC injection of 1 mg/kg SHP681 in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD): 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single SC injection of 2 mg/kg SHP681 in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD): 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single SC injection of 4 mg/kg SHP681 in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD): Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive single SC injection of placebo matched to SHP681 in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD): 0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD): 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD): 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD): 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD): 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD): Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP681</intervention_name>
    <description>Participants will receive SC injection of SHP681 in the abdomen.</description>
    <arm_group_label>Multiple Ascending Dose (MAD): 0.2 mg/kg</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD): 0.5 mg/kg</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD): 1 mg/kg</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD): 2 mg/kg</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD): 4 mg/kg</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD): 0.2 mg/kg</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD): 0.5 mg/kg</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD): 1 mg/kg</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD): 2 mg/kg</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD): 4 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive SC injection of placebo matched to SHP681 in the abdomen.</description>
    <arm_group_label>Multiple Ascending Dose (MAD): Placebo</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD): Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to voluntarily provide written, signed, and dated informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          -  An understanding, ability, and willingness to fully comply with study procedures and&#xD;
             restrictions.&#xD;
&#xD;
          -  Age 18-50 inclusive at the time of consent. The date of signature of the informed&#xD;
             consent is defined as the beginning of the screening period. This inclusion criterion&#xD;
             will only be assessed at the first screening visit.&#xD;
&#xD;
          -  Male, or non-pregnant, non-lactating female who agrees to comply with any applicable&#xD;
             contraceptive requirements of the protocol or females of non-childbearing potential.&#xD;
&#xD;
          -  Considered &quot;healthy&quot; by the investigator. Healthy status is defined by absence of&#xD;
             evidence of any active or chronic disease or condition based on a detailed medical and&#xD;
             surgical history, a complete physical examination including vital signs, 12-lead&#xD;
             electrocardiogram (ECG), hematology, blood chemistry, and urinalysis.&#xD;
&#xD;
          -  Body mass index between 18.0 kilograms per square meter (kg/m^2) and 30.0 kg/m^2&#xD;
             inclusive with a body weight 50-100 kg (110-220 pounds [lbs]). This inclusion&#xD;
             criterion will only be assessed at the first screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any hematological, hepatic, respiratory, cardiovascular, renal,&#xD;
             neurological or psychiatric disease, gall bladder removal, or current or recurrent&#xD;
             disease that could affect the action, absorption, or disposition of the&#xD;
             investigational product, or clinical or laboratory assessments.&#xD;
&#xD;
          -  Current or relevant history of physical or psychiatric illness, any medical disorder&#xD;
             that may require treatment or render the participant unlikely to fully complete the&#xD;
             study, or any condition that presents undue risk from the investigational product or&#xD;
             procedures.&#xD;
&#xD;
          -  Known or suspected intolerance or hypersensitivity to the investigational product(s),&#xD;
             closely-related compounds, or any of the stated ingredients.&#xD;
&#xD;
          -  Significant illness, as judged by the investigator, within 2 weeks of the first dose&#xD;
             of investigational product.&#xD;
&#xD;
          -  Known history of alcohol or other substance abuse within the last year.&#xD;
&#xD;
          -  Donation of blood or blood products (example [eg], plasma or platelets) within 60 days&#xD;
             prior to receiving the first dose of investigational product.&#xD;
&#xD;
          -  Within 30 days prior to the first dose of investigational product:&#xD;
&#xD;
               1. Have used an investigational product (if elimination half-life is less than (&lt;) 6&#xD;
                  days, otherwise 5 half-lives).&#xD;
&#xD;
               2. Have been enrolled in a clinical study.&#xD;
&#xD;
               3. Have had any substantial changes in eating habits, as assessed by the&#xD;
                  investigator.&#xD;
&#xD;
          -  Use of dipeptidyl peptidase (DPP)-4 inhibitors within 30 days or 5 half-lives,&#xD;
             whichever is greater, prior to administration of the investigational product.&#xD;
&#xD;
          -  Confirmed systolic blood pressure greater than (&gt;) 139 millimeters of mercury (mmHg)&#xD;
             or &lt;89mmHg, and diastolic blood pressure &gt; 89mmHg or &lt;49 mmHg.&#xD;
&#xD;
          -  Twelve-lead ECG demonstrating corrected QT interval by Fredericia (QTcF) &gt;450&#xD;
             millisecond (msec) at screening. If QTcF exceeds 450 msec, the ECG should be repeated&#xD;
             2 more times and the average of the 3 QTcF values should be used to determine the&#xD;
             participant's eligibility.&#xD;
&#xD;
          -  Positive screen for alcohol or illicit drugs at screening or Day -1.&#xD;
&#xD;
          -  Male participants who consume more than 21 units of alcohol per week or 3 units per&#xD;
             day. Female participants who consume more than 14 units of alcohol per week or 2 units&#xD;
             per day.&#xD;
&#xD;
             (1 alcohol unit equal to [=] 1 beer or 1 wine (5 ounce [oz] per 150 milliliter [mL])&#xD;
             or 1 liquor (1.5 oz/40 mL) or 0.75 oz alcohol).&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or&#xD;
             hepatitis C virus (HCV) antibody screen.&#xD;
&#xD;
          -  Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing&#xD;
             products in any form (eg, gum, patch). Ex-users must report that they have stopped&#xD;
             using tobacco for at least 30 days prior to receiving the first dose of&#xD;
             investigational product.&#xD;
&#xD;
          -  Routine consumption of more than 2 units of caffeine per day or participants who&#xD;
             experience headaches associated with caffeine withdrawal. (1 caffeine unit is&#xD;
             contained in the following items: one 6 oz (180 mL) cup of coffee, two 12 oz (360 mL)&#xD;
             cans of cola, one 12 oz cup of tea, three 1 oz (85 g) chocolate bars. Decaffeinated&#xD;
             coffee, tea, or cola are not considered to contain caffeine).&#xD;
&#xD;
          -  Prior screen failure (unless Sponsor approval is given), randomization, participation,&#xD;
             or enrollment in this study or prior exposure to any GLP-2 analogs.&#xD;
&#xD;
          -  Unresected gastrointestinal (GI) polyp, known polyposis condition, or premalignant&#xD;
             changes in the GI tract.&#xD;
&#xD;
          -  Any history of malignancy in the GI tract or treatment for any other malignancy in the&#xD;
             previous 5 years.&#xD;
&#xD;
          -  Current use of any medication (including over-the-counter, herbal, or homeopathic&#xD;
             preparations; with the exception of hormonal replacement therapy or hormonal&#xD;
             contraceptives and occasional use of ibuprofen or acetaminophen and pre-approved&#xD;
             medication for sedation or other medications required during or after the endoscopy).&#xD;
             Current use is defined as use within 14 days of the first dose of investigational&#xD;
             product.&#xD;
&#xD;
          -  Findings of subclinical hepatobiliary disease, such as gallstones, on abdominal&#xD;
             ultrasound at screening as determined by the Investigator in consultation with the&#xD;
             Medical Monitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <results_first_submitted>December 23, 2020</results_first_submitted>
  <results_first_submitted_qc>February 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2021</results_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03859323/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03859323/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at single site in United States of America from 25 March 2019 (first participant first visit) and 06 January 2020 (last participant last visit).</recruitment_details>
      <pre_assignment_details>This study consisted of 2 parts: Part A - single ascending dose (SAD) and Part B - multiple ascending dose (MAD). A total of 104 participants were randomized in 2 parts with 30 participants to SAD and 74 participants to MAD, out of which 95 participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Single Ascending Dose (SAD): Placebo</title>
          <description>Participants received single subcutaneous (SC) injection of placebo matched to SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
          <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
          <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
          <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
          <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
          <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Part 2: Multiple Ascending Dose (MAD): Placebo</title>
          <description>Participants received SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="P8">
          <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
          <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="P9">
          <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
          <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="P10">
          <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
          <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="P11">
          <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
          <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="P12">
          <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
          <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="P13">
          <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
          <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="10"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="10"/>
                <participants group_id="P13" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set (SAS) included participants who had received at least one dose of TAK-681 or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Single Ascending Dose (SAD): Placebo</title>
          <description>Participants received single subcutaneous (SC) injection of placebo matched to SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
          <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
          <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
          <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
          <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
          <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Part 2: Multiple Ascending Dose (MAD): Placebo</title>
          <description>Participants received SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="B8">
          <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
          <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="B9">
          <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
          <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="B10">
          <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
          <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="B11">
          <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
          <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="B12">
          <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
          <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="B13">
          <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
          <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="10"/>
            <count group_id="B9" value="10"/>
            <count group_id="B10" value="10"/>
            <count group_id="B11" value="10"/>
            <count group_id="B12" value="12"/>
            <count group_id="B13" value="10"/>
            <count group_id="B14" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6" spread="12.93"/>
                    <measurement group_id="B2" value="28.8" spread="7.60"/>
                    <measurement group_id="B3" value="38.0" spread="9.19"/>
                    <measurement group_id="B4" value="41.4" spread="8.32"/>
                    <measurement group_id="B5" value="33.0" spread="7.35"/>
                    <measurement group_id="B6" value="29.8" spread="3.96"/>
                    <measurement group_id="B7" value="31.2" spread="9.34"/>
                    <measurement group_id="B8" value="32.1" spread="8.63"/>
                    <measurement group_id="B9" value="32.5" spread="9.47"/>
                    <measurement group_id="B10" value="28.4" spread="9.52"/>
                    <measurement group_id="B11" value="32.7" spread="9.38"/>
                    <measurement group_id="B12" value="29.8" spread="10.38"/>
                    <measurement group_id="B13" value="32.0" spread="8.45"/>
                    <measurement group_id="B14" value="32.0" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="11"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="10"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Based on Severity to SHP681 in Single Ascending Dose (SAD)</title>
        <description>Adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with study or use of investigational drug product (IP), whether or not the AE was considered related to IP. TEAEs: AEs occurring or worsening at or after first dose of IP or ongoing at time of enrollment. SAE :untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. Severity: Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 29 for SAD)</time_frame>
        <population>SAS included participants who had received at least 1 dose of SHP681 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): Placebo</title>
            <description>Participants received single subcutaneous (SC) injection of placebo matched to SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Based on Severity to SHP681 in Single Ascending Dose (SAD)</title>
          <description>Adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with study or use of investigational drug product (IP), whether or not the AE was considered related to IP. TEAEs: AEs occurring or worsening at or after first dose of IP or ongoing at time of enrollment. SAE :untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. Severity: Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.</description>
          <population>SAS included participants who had received at least 1 dose of SHP681 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Mild TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Moderate TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Severe TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Based on Severity to SHP681 in Multiple Ascending Dose (MAD)</title>
        <description>AE was any unfavorable and unintended sign, symptom, or disease temporally associated with study or use of investigational drug product (IP), whether or not the AE was considered related to IP. TEAEs: AEs occurring or worsening at or after first dose of IP or ongoing at time of enrollment. SAE :untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. Severity: Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 57 for MAD)</time_frame>
        <population>SAS included participants who had received at least 1 dose of SHP681 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): Placebo</title>
            <description>Participants received SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Based on Severity to SHP681 in Multiple Ascending Dose (MAD)</title>
          <description>AE was any unfavorable and unintended sign, symptom, or disease temporally associated with study or use of investigational drug product (IP), whether or not the AE was considered related to IP. TEAEs: AEs occurring or worsening at or after first dose of IP or ongoing at time of enrollment. SAE :untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. Severity: Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.</description>
          <population>SAS included participants who had received at least 1 dose of SHP681 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Mild TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Moderate TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Severe TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-drug Antibody (ADA) to SHP681 in Single Ascending Dose (SAD) at Day 29</title>
        <description>Antibody testing was conducted using an electro chemiluminescent signal method. Number of participants with ADA to SHP681 in SAD at Day 29 were reported.</description>
        <time_frame>Day 29</time_frame>
        <population>SAS included participants who had received at least 1 dose of SHP681 or placebo. Here, the number of participants analyzed refer to the participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): Placebo</title>
            <description>Participants received single subcutaneous (SC) injection of placebo matched to SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-drug Antibody (ADA) to SHP681 in Single Ascending Dose (SAD) at Day 29</title>
          <description>Antibody testing was conducted using an electro chemiluminescent signal method. Number of participants with ADA to SHP681 in SAD at Day 29 were reported.</description>
          <population>SAS included participants who had received at least 1 dose of SHP681 or placebo. Here, the number of participants analyzed refer to the participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-drug Antibody (ADA) to SHP681 in Multiple Ascending Dose (MAD) at Day 36</title>
        <description>Antibody testing was conducted using an electro chemiluminescent signal method. Number of participants with ADA to SHP681 in MAD at Day 36 were reported.</description>
        <time_frame>Day 36</time_frame>
        <population>SAS included participants who had received at least 1 dose of SHP681 or placebo. Here, the number of participants analyzed refer to the participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): Placebo</title>
            <description>Participants received SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-drug Antibody (ADA) to SHP681 in Multiple Ascending Dose (MAD) at Day 36</title>
          <description>Antibody testing was conducted using an electro chemiluminescent signal method. Number of participants with ADA to SHP681 in MAD at Day 36 were reported.</description>
          <population>SAS included participants who had received at least 1 dose of SHP681 or placebo. Here, the number of participants analyzed refer to the participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-drug Antibody (ADA) to SHP681 in Multiple Ascending Dose (MAD) at Day 57</title>
        <description>Antibody testing was conducted using an electro chemiluminescent signal method. Number of participants with ADA to SHP681 in MAD at Day 57 were reported.</description>
        <time_frame>Day 57</time_frame>
        <population>SAS included participants who had received at least 1 dose of SHP681 or placebo. Here, the number of participants analyzed refer to the participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): Placebo</title>
            <description>Participants received SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-drug Antibody (ADA) to SHP681 in Multiple Ascending Dose (MAD) at Day 57</title>
          <description>Antibody testing was conducted using an electro chemiluminescent signal method. Number of participants with ADA to SHP681 in MAD at Day 57 were reported.</description>
          <population>SAS included participants who had received at least 1 dose of SHP681 or placebo. Here, the number of participants analyzed refer to the participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>Cmax of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
        <population>Pharmacokinetic (PK) analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>Cmax of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>Pharmacokinetic (PK) analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>Micrograms per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8399" spread="73.2"/>
                    <measurement group_id="O2" value="1.515" spread="27.7"/>
                    <measurement group_id="O3" value="4.200" spread="26.8"/>
                    <measurement group_id="O4" value="8.647" spread="28.4"/>
                    <measurement group_id="O5" value="18.39" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of the Last Measurable Concentration (Tlast) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>tlast of SHP681 during SAD was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of the Last Measurable Concentration (Tlast) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>tlast of SHP681 during SAD was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335.0" lower_limit="312" upper_limit="504"/>
                    <measurement group_id="O2" value="504.0" lower_limit="504" upper_limit="672"/>
                    <measurement group_id="O3" value="673.0" lower_limit="671" upper_limit="696"/>
                    <measurement group_id="O4" value="672.0" lower_limit="648" upper_limit="673"/>
                    <measurement group_id="O5" value="672.0" lower_limit="168" upper_limit="673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>tmax of SHP681 during SAD was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>tmax of SHP681 during SAD was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00" lower_limit="24.0" upper_limit="96.0"/>
                    <measurement group_id="O2" value="72.00" lower_limit="48.0" upper_limit="96.0"/>
                    <measurement group_id="O3" value="48.00" lower_limit="48.0" upper_limit="72.0"/>
                    <measurement group_id="O4" value="72.00" lower_limit="48.0" upper_limit="96.0"/>
                    <measurement group_id="O5" value="72.00" lower_limit="48.0" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-last) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>AUC0-last of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-last) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>AUC0-last of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>Hour*microgram per milliliter (h*mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.4" spread="43.7"/>
                    <measurement group_id="O2" value="282.1" spread="31.9"/>
                    <measurement group_id="O3" value="794.6" spread="16.3"/>
                    <measurement group_id="O4" value="1722" spread="25.6"/>
                    <measurement group_id="O5" value="3414" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve Extrapolated to Infinity (AUC0-inf) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>AUC0-inf of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Extrapolated to Infinity (AUC0-inf) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>AUC0-inf of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>h*mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.0" spread="36.9"/>
                    <measurement group_id="O2" value="288.6" spread="31.3"/>
                    <measurement group_id="O3" value="808.3" spread="16.4"/>
                    <measurement group_id="O4" value="1739" spread="25.8"/>
                    <measurement group_id="O5" value="3446" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t1/2) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>t1/2 of SHP681 during SAD was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>t1/2 of SHP681 during SAD was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.50" lower_limit="64.9" upper_limit="109"/>
                    <measurement group_id="O2" value="88.40" lower_limit="76.0" upper_limit="104"/>
                    <measurement group_id="O3" value="97.10" lower_limit="90.1" upper_limit="124"/>
                    <measurement group_id="O4" value="95.40" lower_limit="87.8" upper_limit="116"/>
                    <measurement group_id="O5" value="97.80" lower_limit="86.6" upper_limit="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration From Time Zero to 24 Hours Post Dose (Cavg,0-24) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>Cavg,0-24 of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24 hours post-dose</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration From Time Zero to 24 Hours Post Dose (Cavg,0-24) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>Cavg,0-24 of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>Microgram per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3733" spread="227.3"/>
                    <measurement group_id="O2" value="0.6020" spread="41.3"/>
                    <measurement group_id="O3" value="1.995" spread="36.0"/>
                    <measurement group_id="O4" value="3.193" spread="43.7"/>
                    <measurement group_id="O5" value="7.401" spread="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Order Rate Constant Associated With the Terminal (Log-linear) Portion of the Curve (Lambda z) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>Lambda z of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>First Order Rate Constant Associated With the Terminal (Log-linear) Portion of the Curve (Lambda z) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>Lambda z of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>One per hour (1/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008156" spread="23.6"/>
                    <measurement group_id="O2" value="0.007907" spread="14.2"/>
                    <measurement group_id="O3" value="0.006945" spread="12.8"/>
                    <measurement group_id="O4" value="0.007050" spread="10.4"/>
                    <measurement group_id="O5" value="0.007011" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Body Clearance for Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as Dose Divided by AUC0-inf (CL/F) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>CL/F of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance for Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as Dose Divided by AUC0-inf (CL/F) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>CL/F of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>Liter per hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09810" spread="22.6"/>
                    <measurement group_id="O2" value="0.1188" spread="42.9"/>
                    <measurement group_id="O3" value="0.08856" spread="20.6"/>
                    <measurement group_id="O4" value="0.09909" spread="33.7"/>
                    <measurement group_id="O5" value="0.09689" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution Following Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as CL/F Divided by Lambda z (Vz/F) of SHP681 During Single Ascending Dose (SAD)</title>
        <description>Vz/F of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>Pre-dose, 3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
            <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
            <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
            <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
            <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
            <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution Following Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as CL/F Divided by Lambda z (Vz/F) of SHP681 During Single Ascending Dose (SAD)</title>
          <description>Vz/F of SHP681 during SAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.01" spread="37.2"/>
                    <measurement group_id="O2" value="15.02" spread="54.7"/>
                    <measurement group_id="O3" value="12.75" spread="27.8"/>
                    <measurement group_id="O4" value="14.05" spread="35.8"/>
                    <measurement group_id="O5" value="12.98" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration From Time Zero to 24 Hours Post First Dose (Cavg,0-24) of SHP681 Post First Dose During Multiple Ascending Dose (MAD)</title>
        <description>Cavg,0-24 of SHP681 post first dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>3, 6, 12, 24 hours post-dose on Day 1</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration From Time Zero to 24 Hours Post First Dose (Cavg,0-24) of SHP681 Post First Dose During Multiple Ascending Dose (MAD)</title>
          <description>Cavg,0-24 of SHP681 post first dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1716" spread="77.2"/>
                    <measurement group_id="O2" value="0.5091" spread="69.5"/>
                    <measurement group_id="O3" value="1.610" spread="72.0"/>
                    <measurement group_id="O4" value="2.108" spread="39.2"/>
                    <measurement group_id="O5" value="4.598" spread="40.4"/>
                    <measurement group_id="O6" value="5.660" spread="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Concentration at the End of Each Dosing Interval (Immediately Before Next Dose) (Ctrough) of SHP681 for the First 5 Cohorts and Immediately Before 2nd and 3rd Dose of the 6th MAD Cohort During Multiple Ascending Dose (MAD)</title>
        <description>Ctrough of SHP681 for the First 5 cohorts and immediately before 2nd and 3rd dose of the 6th MAD cohort during MAD was reported.</description>
        <time_frame>Pre-dose on Days 8, 15, 22 and 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure at the specific categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Concentration at the End of Each Dosing Interval (Immediately Before Next Dose) (Ctrough) of SHP681 for the First 5 Cohorts and Immediately Before 2nd and 3rd Dose of the 6th MAD Cohort During Multiple Ascending Dose (MAD)</title>
          <description>Ctrough of SHP681 for the First 5 cohorts and immediately before 2nd and 3rd dose of the 6th MAD cohort during MAD was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure at the specific categories.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3523" spread="39.2"/>
                    <measurement group_id="O2" value="0.8432" spread="28.2"/>
                    <measurement group_id="O3" value="1.754" spread="11.9"/>
                    <measurement group_id="O4" value="4.062" spread="23.5"/>
                    <measurement group_id="O5" value="6.949" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4688" spread="27.7"/>
                    <measurement group_id="O2" value="1.182" spread="30.6"/>
                    <measurement group_id="O3" value="2.332" spread="20.6"/>
                    <measurement group_id="O4" value="5.312" spread="14.6"/>
                    <measurement group_id="O5" value="9.888" spread="28.5"/>
                    <measurement group_id="O6" value="2.931" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4593" spread="26.5"/>
                    <measurement group_id="O2" value="1.146" spread="25.1"/>
                    <measurement group_id="O3" value="2.707" spread="12.3"/>
                    <measurement group_id="O4" value="5.249" spread="18.8"/>
                    <measurement group_id="O5" value="13.09" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5288" spread="24.8"/>
                    <measurement group_id="O2" value="1.203" spread="25.8"/>
                    <measurement group_id="O3" value="2.659" spread="14.4"/>
                    <measurement group_id="O4" value="5.775" spread="27.4"/>
                    <measurement group_id="O5" value="12.92" spread="26.7"/>
                    <measurement group_id="O6" value="3.109" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration During the Dosing Interval Occurring at Tmax (Cmax) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>Cmax of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration During the Dosing Interval Occurring at Tmax (Cmax) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>Cmax of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9710" spread="38.0"/>
                    <measurement group_id="O2" value="2.215" spread="39.5"/>
                    <measurement group_id="O3" value="4.819" spread="19.6"/>
                    <measurement group_id="O4" value="10.38" spread="34.3"/>
                    <measurement group_id="O5" value="24.15" spread="28.2"/>
                    <measurement group_id="O6" value="14.45" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of the Last Measurable Concentration (Tlast) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>Tlast of SHP681 post fifth dose during MAD was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of the Last Measurable Concentration (Tlast) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>Tlast of SHP681 post fifth dose during MAD was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="504.0" lower_limit="504" upper_limit="672"/>
                    <measurement group_id="O2" value="672.0" lower_limit="503" upper_limit="674"/>
                    <measurement group_id="O3" value="672.5" lower_limit="669" upper_limit="674"/>
                    <measurement group_id="O4" value="672.0" lower_limit="672" upper_limit="673"/>
                    <measurement group_id="O5" value="672.0" lower_limit="647" upper_limit="672"/>
                    <measurement group_id="O6" value="672.0" lower_limit="623" upper_limit="768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>tmax of SHP681 post fifth dose during MAD was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>tmax of SHP681 post fifth dose during MAD was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.00" lower_limit="12.0" upper_limit="168"/>
                    <measurement group_id="O2" value="36.00" lower_limit="3.00" upper_limit="96.0"/>
                    <measurement group_id="O3" value="48.00" lower_limit="24.0" upper_limit="96.0"/>
                    <measurement group_id="O4" value="48.00" lower_limit="12.0" upper_limit="72.0"/>
                    <measurement group_id="O5" value="48.00" lower_limit="48.0" upper_limit="72.0"/>
                    <measurement group_id="O6" value="72.00" lower_limit="48.0" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve for the Defined Interval Between Doses (Only Calculated if Interpretable) (AUC0-tau) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>AUC0-tau of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for the Defined Interval Between Doses (Only Calculated if Interpretable) (AUC0-tau) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>AUC0-tau of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>h*mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.6" spread="33.2"/>
                    <measurement group_id="O2" value="282.1" spread="36.2"/>
                    <measurement group_id="O3" value="645.2" spread="18.7"/>
                    <measurement group_id="O4" value="1344" spread="32.6"/>
                    <measurement group_id="O5" value="3297" spread="24.8"/>
                    <measurement group_id="O6" value="2816" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-last) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>AUC0-last of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-last) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>AUC0-last of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>h*mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.8" spread="29.1"/>
                    <measurement group_id="O2" value="435.2" spread="33.8"/>
                    <measurement group_id="O3" value="991.4" spread="16.3"/>
                    <measurement group_id="O4" value="2177" spread="29.9"/>
                    <measurement group_id="O5" value="5456" spread="22.8"/>
                    <measurement group_id="O6" value="3230" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve Extrapolated to Infinity (AUC0-inf) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>AUC0-inf of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Extrapolated to Infinity (AUC0-inf) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>AUC0-inf of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>h*mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.4" spread="28.5"/>
                    <measurement group_id="O2" value="443.1" spread="33.5"/>
                    <measurement group_id="O3" value="1006" spread="16.3"/>
                    <measurement group_id="O4" value="2216" spread="29.6"/>
                    <measurement group_id="O5" value="5548" spread="22.8"/>
                    <measurement group_id="O6" value="3277" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration From Time Zero to 24 Hours Post Dose (Cavg,0-24) of SHP681 During Multiple Ascending Dose (MAD)</title>
        <description>Cavg,0-24 of SHP681 during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration From Time Zero to 24 Hours Post Dose (Cavg,0-24) of SHP681 During Multiple Ascending Dose (MAD)</title>
          <description>Cavg,0-24 of SHP681 during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6956" spread="42.3"/>
                    <measurement group_id="O2" value="1.683" spread="36.9"/>
                    <measurement group_id="O3" value="3.619" spread="20.8"/>
                    <measurement group_id="O4" value="7.942" spread="22.3"/>
                    <measurement group_id="O5" value="17.04" spread="23.4"/>
                    <measurement group_id="O6" value="7.006" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t1/2) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>t1/2 of SHP681 post fifth dose during MAD was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>t1/2 of SHP681 post fifth dose during MAD was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.30" lower_limit="82.6" upper_limit="116"/>
                    <measurement group_id="O2" value="108.5" lower_limit="81.3" upper_limit="130"/>
                    <measurement group_id="O3" value="103.5" lower_limit="96.6" upper_limit="116"/>
                    <measurement group_id="O4" value="105.0" lower_limit="98.2" upper_limit="131"/>
                    <measurement group_id="O5" value="106.5" lower_limit="96.4" upper_limit="131"/>
                    <measurement group_id="O6" value="99.10" lower_limit="92.3" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Order Rate Constant Associated With the Terminal (Log-linear) Portion of the Curve (Lambda z) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>Lambda z of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>First Order Rate Constant Associated With the Terminal (Log-linear) Portion of the Curve (Lambda z) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>Lambda z of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007215" spread="9.4"/>
                    <measurement group_id="O2" value="0.006667" spread="14.3"/>
                    <measurement group_id="O3" value="0.006633" spread="6.3"/>
                    <measurement group_id="O4" value="0.006416" spread="8.7"/>
                    <measurement group_id="O5" value="0.006473" spread="9.8"/>
                    <measurement group_id="O6" value="0.006922" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Body Clearance Following Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as Dose Divided by AUCtau (CL/F) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>CL/F of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance Following Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as Dose Divided by AUCtau (CL/F) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>CL/F of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1225" spread="38.5"/>
                    <measurement group_id="O2" value="0.1366" spread="53.5"/>
                    <measurement group_id="O3" value="0.1141" spread="21.3"/>
                    <measurement group_id="O4" value="0.1226" spread="35.5"/>
                    <measurement group_id="O5" value="0.09547" spread="27.3"/>
                    <measurement group_id="O6" value="0.1100" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution Following Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as CL/F Divided by Lambda z (Vz/F) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
        <description>Vz/F of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 and up to 768 hours post--dose on Day 29</time_frame>
        <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
            <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
            <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
            <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
            <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
            <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
            <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution Following Extravascular Administration Divided by the Fraction of Dose Absorbed Calculated as CL/F Divided by Lambda z (Vz/F) of SHP681 Post Fifth Dose During Multiple Ascending Dose (MAD)</title>
          <description>Vz/F of SHP681 post fifth dose during MAD was reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.</description>
          <population>PK analysis set consisted of participants who received at least 1 dose of SHP681 and had at least 1 evaluable post-dose PK concentration value which was evaluable and interpretable. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.99" spread="39.4"/>
                    <measurement group_id="O2" value="20.48" spread="56.4"/>
                    <measurement group_id="O3" value="17.21" spread="24.0"/>
                    <measurement group_id="O4" value="19.12" spread="42.2"/>
                    <measurement group_id="O5" value="14.75" spread="30.8"/>
                    <measurement group_id="O6" value="15.89" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug administration up to follow-up (Day 29 for SAD / Day 57 for MAD)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Single Ascending Dose (SAD): Placebo</title>
          <description>Participants received single subcutaneous (SC) injection of placebo matched to SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Single Ascending Dose (SAD): 0.2 mg/kg</title>
          <description>Participants received single SC injection of 0.2 milligrams per kilogram (mg/kg) SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: Single Ascending Dose (SAD): 0.5 mg/kg</title>
          <description>Participants received single SC injection of 0.5 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: Single Ascending Dose (SAD): 1 mg/kg</title>
          <description>Participants received single SC injection of 1 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 1: Single Ascending Dose (SAD): 2 mg/kg</title>
          <description>Participants received single SC injection of 2 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Part 1: Single Ascending Dose (SAD): 4 mg/kg</title>
          <description>Participants received single SC injection of 4 mg/kg SHP681 in the abdomen on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Part 2: Multiple Ascending Dose (MAD): Placebo</title>
          <description>Participants received SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="E8">
          <title>Part 2: Multiple Ascending Dose (MAD): 0.2 mg/kg</title>
          <description>Participants received SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="E9">
          <title>Part 2: Multiple Ascending Dose (MAD): 0.5 mg/kg</title>
          <description>Participants received SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="E10">
          <title>Part 2: Multiple Ascending Dose (MAD): 1 mg/kg</title>
          <description>Participants received SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="E11">
          <title>Part 2: Multiple Ascending Dose (MAD): 2 mg/kg</title>
          <description>Participants received SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="E12">
          <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg</title>
          <description>Participants received SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen up to Day 29.</description>
        </group>
        <group group_id="E13">
          <title>Part 2: Multiple Ascending Dose (MAD): 4 mg/kg (Q2W)</title>
          <description>Participants received SC injection of placebo matched to SHP681 twice weekly (Q2W) for 5 weeks in the abdomen up to Day 29.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" events="8" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
      <email>ClinicalTransparency@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

